Insider trade

Officer sold ~$5.88M of MRNA shares in the open market

Traded Sep 15, 2026 · Filed Sep 16, 2026

ModernaMRNA

~$5.88M
Reported value · 40K sh @ $146.07: 1.56M
Holds after · shares reported: +31.4%
stock since the trade · S&P 500 +0.9%, $143.77 → $188.94 on Oct 1

Why it stands out

Moderna's President sold $5.88M of Moderna shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Sep 15, 2026
Reporting period: Not applicable
Filed with the SEC: Sep 16, 2026

Officer$1M+Pre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$5,883,846

Shares × reported transaction price

Timing vs results

46 days after results of Jul 31, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $143.77 on Sep 15, 2026, 543% above its 52-week low and 18% below its high, after a 161% rise over the previous 30 trading days

52-week range $22.36 (Nov 20, 2025) to $174.38 (Aug 19, 2026), 80% of the way up, from 251 adjusted closes. 30 trading days earlier: $55.14 on Aug 3, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Aug 9, 2024 in the U.S. District Court, D. Massachusetts. A filing is an allegation, not a finding.

Wentz v. Moderna, Inc., docket 1:24-cv-12058, via CourtListener (court records). Nature of suit 850, company named as first defendant

After it was reported

After	Stock	S&P 500	Difference
7 days	+23.3%	+0.6%	+22.6%

Past results only. Not a forecast.

Source receipt

Record ID: 0001682852-26-000176
Filed / recorded: Sep 16, 2026, 8:48 PM UTC
Added to OQRO: Oct 2, 2026, 12:28 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: Moderna, Inc.
Issuer CIK: 1682852
Ticker: MRNA
Reporting person: Stephen Hoge
Relationship: Officer
Officer title: President
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Sep 15, 2026
Transaction code: S
Shares / units: 40,281
Price per share: $146.07
Acquired / disposed: Disposed (D)
Shares owned after: 1,562,029
Ownership form: Direct
Amendment: No

Footnotes from the filing

The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.97 to $146.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Around the same time

3w ago

76KShares · @ $12.21

Derivative exercise or conversion — not an open-market buy.

Why it stands out Official record

Officer sold ~$5.81M of Moderna

Scheduled in advance3w ago

3w ago

76KShares · @ $12.21

Derivative exercise or conversion — not an open-market buy.

Why it stands out Official record